New Two-Drug attack tested for Tough-to-Treat sarcomas
NCT ID NCT06498648
Summary
This study is testing a new treatment approach for people with advanced soft tissue sarcomas, including leiomyosarcoma and dedifferentiated liposarcoma. It aims to find the safest dose and best schedule for combining the drug abemaciclib with chemotherapy (gemcitabine). The main goal is to see if this new combination can help control the cancer for longer than the current standard chemotherapy treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC DEDIFFERENTIATED LIPOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.